<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26889974</article-id><article-id pub-id-type="pmc">4800295</article-id><article-id pub-id-type="pii">bjc201623</article-id><article-id pub-id-type="doi">10.1038/bjc.2016.23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study</article-title><alt-title alt-title-type="running">dNLR is predictive of survival from intermittent therapy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grenader</surname><given-names>Tal</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nash</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fisher</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Maughan</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bridgewater</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Oncology Institute, Shaare Zedek Medical Centre</institution>, Serusatem, Israel</aff><aff id="aff2"><label>2</label><institution>Cancer Research UK &#x00026; UCL Cancer Trials Centre</institution>, London WIT 4TJ4TJ, UK</aff><aff id="aff3"><label>3</label><institution>Institute of Cancer &#x00026; Genetics, Cardiff University School of Medicine Velindre Hospital</institution>, Cardiff CF14 2TL, UK</aff><aff id="aff4"><label>4</label><institution>MRC Clinical Trials Unit at UCL</institution>, London WC2B 6NH, UK</aff><aff id="aff5"><label>5</label><institution>CRUK/MRC Oxford Institute for Radiation</institution>, Oxford OX3 7DQ, UK</aff><aff id="aff6"><label>6</label><institution>UCL Cancer Institute</institution>, London WC1E 6DD, <country>UK</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>j.bridgewater@ucl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>03</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2016</year></pub-date><volume>114</volume><issue>6</issue><fpage>612</fpage><lpage>615</lpage><history><date date-type="received"><day>09</day><month>09</month><year>2015</year></date><date date-type="rev-recd"><day>24</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>01</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Cancer Research UK</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link></license-p></license></permissions><abstract><sec><title>Background:</title><p>The phase III COntinuous or INtermittent (COIN) trial failed to show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in overall survival (OS). The present analysis evaluated whether the derived neutrophil to lymphocyte ratio (dNLR) could predict the effect of intermittent <italic>vs</italic> continuous chemotherapy on OS in patients with advanced colorectal cancer.</p></sec><sec><title>Methods:</title><p>A post hoc exploratory analysis of COIN arms A and C was performed. Landmark analysis was conducted on all patients with available WBC and neutrophils data. The dNLR was calculated using a formula which has previously demonstrated predictive power in cancer patients: dNLR=ANC/(WBC&#x02212;ANC). A high dNLR was defined using a cut-off value of &#x02a7e;2.22. Derived neutrophil to lymphocyte ratio was then correlated with clinical outcomes. Survival curves were generated based on dNLR using the Kaplan&#x02013;Meier method. Comparison between groups was performed using Cox regression.</p></sec><sec><title>Results:</title><p>A total of 1630 patients were assigned to the continuous (<italic>N</italic>=815) or intermittent (<italic>N</italic>=815) arms. There was a strong association between dNLR level and OS. The median survival times in the ITT population were 18.6 months and 12.5 months for patients with low and high dNLR, respectively (HR=1.70; 95&#x00025; CI=1.52&#x02013;1.90; <italic>P</italic>&#x0003c;0.001). The estimate of the hazard ratio did not alter substantially (HR=1.54) after adjusting for treatment, tumour status, number of metastatic sites, alkaline phosphate and platelet count.</p></sec><sec><title>Conclusions:</title><p>Derived neutrophil to lymphocyte ratio is strongly prognostic for survival in the COIN intermittent <italic>vs</italic> continuous treatment arms. Derived neutrophil to lymphocyte ratio does not predict for detrimental survival in patients treated with intermittent therapy.</p></sec></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>neutrophil lymphocyte ratio</kwd><kwd>prognostic</kwd><kwd>predictive</kwd><kwd>intermittent therapy</kwd></kwd-group></article-meta></front><body><p>The treatment of advanced colorectal cancer has improved substantially during the past decade with the introduction of new and more effective drugs and advances in our understanding of the disease's molecular biology (<xref ref-type="bibr" rid="bib3">Douillard <italic>et al.</italic>, 2013</xref>). However, the balance between improved survival and costs, in terms of toxicity, quality of life and financial, can be difficult. The COIN trial (COntinuous or INtermittent) was developed to conclusively address this issue (<xref ref-type="bibr" rid="bib1">Adams <italic>et al.</italic>, 2011</xref>). Approximately 1600 patients with advanced colorectal cancer were randomised to receive intermittent <italic>vs</italic> continuous systemic therapy with oxaliplatin and fluoropyrimidine. Although the trial did not show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in terms of overall survival, a subgroup analysis suggests that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemotherapy, and may do better without a treatment break.</p><p>Numerous studies have established that elevated inflammatory markers, such as C-reactive protein, neutrophil/lymphocyte ratio (NLR) and platelet-lymphocyte ratio have been associated with poor outcomes in cancer patients with colorectal cancer (<xref ref-type="bibr" rid="bib7">Walsh <italic>et al.</italic>, 2005</xref>; <xref ref-type="bibr" rid="bib4">Liu <italic>et al.</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib5">Proctor <italic>et al.</italic>, 2012</xref>). Platelets count and neutrophil lymphocyte ratio are inexpensive markers of host inflammation, and may reflect cytokine activation and more aggressive disease. A recently reported meta-analysis of 100 studies comprising 40&#x02009;559 patients found NLR &#x0003e; 4 was associated with poorer OS with hazard ratio for OS of 1.81 (95&#x00025; CI=1.67&#x02013;1.97; <italic>P</italic>&#x0003c;0.001), an effect observed in all disease subgroups, sites, and stages (<xref ref-type="bibr" rid="bib6">Templeton <italic>et al.</italic>, 2014</xref>). Lymphocyte count data was not collected in the COIN trial, however the derived NLR (dNLR) has been shown to possess similar prognostic value (<xref ref-type="bibr" rid="bib2">Dirican <italic>et al.</italic>, 2014</xref>).</p><p>The aim of the present correlative analysis was to evaluate whether dNLR could predict the effect of intermittent <italic>vs</italic> continuous first-line oxaliplatin and fluoropyrimidine chemotherapy on overall survival in patients with advanced colorectal cancer.</p><sec><title>Materials and methods</title><p>The trial design and eligibility criteria have been reported previously (<xref ref-type="bibr" rid="bib1">Adams <italic>et al.</italic>, 2011</xref>). The primary objective of the phase 3 MRC COIN study was to assess the effect of pre-planned treatment interruptions in oxaliplatin and fluoropyrimidine combination chemotherapy on overall survival. A second randomisation in the trial assessed the effect of addition of cetuximab to continuous oxaliplatin and fluoropyrimidine combination chemo therapy.</p><p>After enrolment, patients were randomly assigned (1) to the control arm of continuous (arm A) or intermittent (arm C) chemotherapy. In arm A treatment was continued until disease progression, development of cumulative toxic effects, or patient choice. Patients on arm C received chemotherapy for 12 weeks, after which treatment was stopped completely and the patients were assessed with imaging every 12 weeks. The same chemotherapy was restarted on progression.</p><sec><title>Derived neutrophil/lymphocyte ratio (dNLR) calculation</title><p>White blood cell (WBC) and absolute neutrophil count (ANC) were obtained at patient enrolment. The dNLR was calculated using a formula that was previously shown to have predictive power in cancer patients (<xref ref-type="bibr" rid="bib7">Walsh <italic>et al.</italic>, 2005</xref>; <xref ref-type="bibr" rid="bib2">Dirican <italic>et al.</italic>, 2014</xref>).</p></sec><sec><title>Statistical methods</title><p>All statistical analyses were performed by the Cancer Research UK and University College London Cancer Trials Centre. All randomly assigned patients for whom data on WBC and ANC in patient enrolment were available were included in the analysis. A high dNLR was defined using a cut-off value of 2.2, which was the median dNLR.</p><p>Associations were assessed using Kaplan&#x02013;Meier plots and Cox proportional hazard models. An interaction between dNLR (&#x0003c;2.22) and treatment allocation was used to assess the difference in treatment effects between the two trial arms. Models were adjusted for the <italic>a priori</italic> factors of treatment arm (standard, intermittent), tumour status (resected, locally recurrent, unresected), number of metastatic sites (0 or 1, 2 or more), CEA at baseline (&#x0003c;100, &#x02a7e;100&#x02009;mg&#x02009;l<sup>&#x02212;1</sup>), alkaline phosphatase at baseline (&#x0003c;100, &#x02a7e;100&#x02009;U&#x02009;l<sup>&#x02212;1</sup>) and platelet count at baseline (&#x0003c;400&#x02009;000 <italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, &#x02a7e;400&#x02009;000 <italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>). Factors were excluded from the model when they were missing for more than 10&#x00025; of the population including CEA. Initial analysis of the association between dNLR and overall survival was performed on the ITT population; all comparisons between treatment groups was performed on both the ITT and the per protocol population, defined as all patients who reached the point where the continuous and intermittent strategies diverged, consistent with the original trial definition. As this was a non-inferiority trial, all comparisons between the treatment groups are reported with 80&#x00025; confidence intervals, with a boundary of 1.162 used to assess non-inferiority (<xref ref-type="bibr" rid="bib1">Adams <italic>et al.</italic>, 2011</xref>). Receiver operating characteristic analysis was performed to calculate area under the curve (AUC) using one-year survival as the outcome and baseline dNLR as the test variable.</p><p>Statistical analysis was carried out using Stata version 12.1 (College Station, TX, USA).</p></sec></sec><sec><title>Results</title><sec><title>Population studied</title><p>A total of 1630 patients were assigned to the continuous (<italic>N</italic>=815) or intermittent (<italic>N</italic>=815) arms. There was incomplete data for 32 patients (<italic>N</italic>=8 for missing dates, <italic>N</italic>=55 for missing platelets, <italic>N</italic>=1313 for missing dNLR) who were excluded, resulting in a cohort of 1604 patients (accounting for 98.4&#x00025; of the total study population). Of these patients, 971 (60.5&#x00025;) remained on study beyond 12 weeks and were included in the per protocol analysis (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p></sec><sec><title>Prognostic</title><p>There was a strong association between dNLR level and overall survival. The median survival times in the ITT population were 18.6 months and 12.5 months for patients with low and high dNLR, respectively (HR=1.70; 95&#x00025; CI=1.52&#x02013;1.90; <italic>P</italic>&#x0003c;0.001). The estimate of the hazard ratio did not alter substantially (HR=1.54) after adjusting for treatment, tumour status, number of metastatic sites, alkaline phosphatase and platelet count (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The AUC was 64.5&#x00025; and there was a detection rate for survival of 82.5&#x00025; and a false positive rate of 63.1&#x00025;. As a comparator, the AUC for platelets was 62.8&#x00025;, and using a value of 400&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup> to dichotomise baseline platelets there was a detection rate of 76.8&#x00025; and a false positive rate of 58.8&#x00025;. Both criteria remain modestly prognostic as previously defined (<xref ref-type="bibr" rid="bib8">Walter, 2002</xref>).</p></sec><sec><title>Predictive effect of high dNLR</title><p>There was no evidence of a differential effect of treatment between the two dNLR groups in the ITT population only (<italic>P</italic>=0.20). Among patients with low baseline dNLR, the hazard ratio for treatment allocation was 1.16 (80&#x00025; CI=1.00&#x02013;1.34) compared to 1.21 (80&#x00025; CI=1.09&#x02013;1.34) among the high dNLR group. In the per protocol population (<italic>N</italic>=971), the hazard ratios were 1.06 and 1.26 for the low and high dNLR groups respectively. There was no evidence to support a differential treatment effect in this population (<italic>P</italic>=0.26 for interaction between dNLR group and treatment allocation), nor evidence of non-inferiority (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref rid="tbl2" ref-type="table">Table 2</xref>).</p><p>As previously reported, a raised platelet count at baseline (&#x02a7e;400&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, recorded for 271 (28&#x00025;) of 978 patients) predicts a significant survival detriment from intermittent chemotherapy (<italic>P</italic>=0.0027 for interaction). Combining platelet count and dNLR as a single predictive factor was not superior to platelet count alone (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>).</p></sec></sec><sec><title>Discussion</title><p>We demonstrate that dNLR is prognostic in the COIN intermittent <italic>vs</italic> continuous comparison but does not add to the platelet count in selecting patients who would benefit from continuous rather than intermittent therapy. Although some cut-off value of &#x02a7e;2.2 did select a population who benefited from continuous treatment, such an approach lacks robust statistical process and we have reported an outcome using the median dNLR of 2.2. We also conclude that the interpretation of dNLR and the platelet count as predictive factors is more complex than these numerical values would suggest.</p><p>A series of studies have proposed that inflammation-based prognostic systems like neutrophil to lymphocyte ratio and thrombocytosis are associated with poor survival of subjects with cancer. A systematic review of 100 studies comprising 40&#x02009;559 patient with various solid tumours found NLR was associated with an adverse OS hazard ratio of 1.81 (95&#x00025; CI=1.67&#x02013;1.97; <italic>P</italic>&#x0003c;0.001) (<xref ref-type="bibr" rid="bib6">Templeton <italic>et al.</italic>, 2014</xref>), an effect observed in all disease subgroups, sites, and stages. In the six prospective studies used in the NLR meta-analysis containing patients with metastatic colorectal cancer, there were a total of 1817 patients.</p><p>The biological mechanism responsible for a higher dNLR requires further investigation, particularly in the context of clinical studies of ruxolitinib and the checkpoint inhibitors. A platelet count of &#x0003e;400 remains the most robust criteria by which to select patients for intermittent therapy, and this is being investigated in the FOCUS-4 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.focus4trial.org/">http://www.focus4trial.org/</ext-link>). Statistical uncertainties with respect to biomarker cut-off values continue to generate difficulties in the interpretation of prognostic and predictive biomarkers.</p><p>In conclusion, both dNLR and platelets counts were prognostic in patients with metastatic colorectal cancer receiving first-line chemotherapy in randomised phase III COIN trial. A high dNLR &#x02a7e;2.22 and platelets &#x02a7e;400&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup> were associated with shorter survival. However, in contrast to platelet count, a high dNLR failed to predict inferiority of intermittent chemotherapy and cannot be used for clinical decision of which patients can benefit from chemotherapy-free breaks.</p></sec></body><back><ack><p>TG is a fellow of the European Society of Medical Oncology. SN was supported by CRUK Grant C444/A15953 to the UCL CRUK Trials Centre. JB is partly supported by the UCLH/UCL Biomedical Research Centre.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on <italic>British Journal of Cancer</italic> website (http://www.nature.com/bjc)</p></fn><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal">Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS MRC COIN Trial Investigators (<year>2011</year>) <article-title>Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial</article-title>. <source>Lancet Oncol</source>
<volume>12</volume>: <fpage>642</fpage>&#x02013;653.<pub-id pub-id-type="pmid">21641867</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, Somali I, Demir L, Bayoglu IV, Yildiz Y, Akyol M, Koyuncu B, Coban E, Ulger E, Unay FC, Tarhan MO (<year>2014</year>) <article-title>Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer</article-title>? <source>Int J Clin Oncol</source>
<volume>20</volume>: <fpage>70</fpage>&#x02013;81.<pub-id pub-id-type="pmid">24532163</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal">Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc&#x000e1;kova I, Ruff P, B&#x00142;asi&#x00144;ska-Morawiec M, &#x00160;makal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (<year>2013</year>) <article-title>Panitumumab&#x02013;FOLFOX4 treatment and RAS mutations in colorectal cancer</article-title>. <source>N Engl J Med</source>
<volume>369</volume>: <fpage>1023</fpage>&#x02013;1034.<pub-id pub-id-type="pmid">24024839</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal">Liu H, Liu G, Bao Q, Sun W, Bao H, Bi L, Wen W, Liu Y, Wang Z, Yin X, Bai Y, Hu X (<year>2010</year>) <article-title>The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma</article-title>. <source>J Gastrointest Cancer</source>
<volume>41</volume>: <fpage>116</fpage>&#x02013;120.<pub-id pub-id-type="pmid">20127292</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (<year>2012</year>) <article-title>A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer</article-title>. <source>Br J Cancer</source>
<volume>107</volume>: <fpage>695</fpage>&#x02013;699.<pub-id pub-id-type="pmid">22828611</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="other">Templeton AJ, McNamara MG, &#x00160;eruga B, Vera-Badillo FE, Aneja P, Oca&#x000f1;a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (<year>2014</year>) <article-title>Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis</article-title>. <source>J Natl Cancer Inst</source> e-pub ahead of print 29 May 2014 doi:10.1093/jnci/dju124.</mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal">Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (<year>2005</year>) <article-title>Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer</article-title>. <source>J Surg Oncol</source>
<volume>91</volume>: <fpage>181</fpage>&#x02013;184.<pub-id pub-id-type="pmid">16118772</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">Walter SD (<year>2002</year>) <article-title>Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data</article-title>. <source>Stat Med</source>
<volume>21</volume>: <fpage>1237</fpage>&#x02013;1256.<pub-id pub-id-type="pmid">12111876</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Table 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc201623x1.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Prognostic impact of dNLR on overall survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc201623f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>(<bold>A</bold>) Impact of low dNLR on overall survival. (<bold>B</bold>) Impact of high dNLR on overall survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc201623f2"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Population demographics by dNLR</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50"><bold>dNLR &#x02a7d; 2.2 (</bold><italic><bold>N</bold></italic><bold>=805)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>dNLR</bold> &#x02a7e; <bold>2.2 (</bold><italic><bold>N</bold></italic><bold>=799)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Treatment</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">A&#x02013;Standard chemotherapy</td><td align="char" valign="top" char="(" charoff="50">391 (48.6)</td><td align="char" valign="top" char="(" charoff="50">408 (51.1)</td></tr><tr><td align="left" valign="top" charoff="50">C&#x02013;Intermittent chemotherapy</td><td align="char" valign="top" char="(" charoff="50">414 (51.4)</td><td align="char" valign="top" char="(" charoff="50">391 (48.9)</td></tr><tr><td align="left" valign="top" charoff="50">Age; median (range)</td><td align="char" valign="top" char="(" charoff="50">63.8 (18-82)</td><td align="char" valign="top" char="(" charoff="50">63.6 (25-87)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Sex</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Male</td><td align="char" valign="top" char="(" charoff="50">538 (66.8)</td><td align="char" valign="top" char="(" charoff="50">499 (62.5)</td></tr><tr><td align="left" valign="top" charoff="50">Female</td><td align="char" valign="top" char="(" charoff="50">267 (33.2)</td><td align="char" valign="top" char="(" charoff="50">300 (37.5)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>WHO performance status</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">0&#x02013;Normal activity without restriction</td><td align="char" valign="top" char="(" charoff="50">417 (51.8)</td><td align="char" valign="top" char="(" charoff="50">320 (40.1)</td></tr><tr><td align="left" valign="top" charoff="50">1&#x02013;Strenuous activity restricted; can do light work</td><td align="char" valign="top" char="(" charoff="50">348 (43.2)</td><td align="char" valign="top" char="(" charoff="50">402 (50.3)</td></tr><tr><td align="left" valign="top" charoff="50">2&#x02013;Up and about &#x0003e;50&#x00025; of waking hours, limited self-care</td><td align="char" valign="top" char="(" charoff="50">40 (5.0)</td><td align="char" valign="top" char="(" charoff="50">77 (9.6)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Status of primary tumour</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Resected</td><td align="char" valign="top" char="(" charoff="50">485 (60.2)</td><td align="char" valign="top" char="(" charoff="50">364 (45.6)</td></tr><tr><td align="left" valign="top" charoff="50">Local recurrence</td><td align="char" valign="top" char="(" charoff="50">40 (5.0)</td><td align="char" valign="top" char="(" charoff="50">44 (5.5)</td></tr><tr><td align="left" valign="top" charoff="50">Unresected/unresectable</td><td align="char" valign="top" char="(" charoff="50">280 (34.8)</td><td align="char" valign="top" char="(" charoff="50">391 (48.9)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Number of metastatic sites</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">5 (0.6)</td><td align="char" valign="top" char="(" charoff="50">8 (1.0)</td></tr><tr><td align="left" valign="top" charoff="50">1</td><td align="char" valign="top" char="(" charoff="50">295 (36.6)</td><td align="char" valign="top" char="(" charoff="50">262 (32.8)</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="char" valign="top" char="(" charoff="50">326 (40.5)</td><td align="char" valign="top" char="(" charoff="50">316 (39.5)</td></tr><tr><td align="left" valign="top" charoff="50">3&#x0002b;</td><td align="char" valign="top" char="(" charoff="50">179 (22.2)</td><td align="char" valign="top" char="(" charoff="50">213 (26.7)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Liver-only metastases</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">No</td><td align="char" valign="top" char="(" charoff="50">623 (77.4)</td><td align="char" valign="top" char="(" charoff="50">634 (79.3)</td></tr><tr><td align="left" valign="top" charoff="50">Yes</td><td align="char" valign="top" char="(" charoff="50">182 (22.6)</td><td align="char" valign="top" char="(" charoff="50">165 (20.7)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Platelets</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x0003c;400&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup></td><td align="char" valign="top" char="(" charoff="50">633 (78.6)</td><td align="char" valign="top" char="(" charoff="50">490 (61.3)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02a7e;400&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup></td><td align="char" valign="top" char="(" charoff="50">172 (21.4)</td><td align="char" valign="top" char="(" charoff="50">309 (38.7)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>CEA</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x0003c;100</td><td align="char" valign="top" char="(" charoff="50">402 (65.0)</td><td align="char" valign="top" char="(" charoff="50">319 (50.2)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02a7e; 100</td><td align="char" valign="top" char="(" charoff="50">216 (35.0)</td><td align="char" valign="top" char="(" charoff="50">316 (49.8)</td></tr><tr><td align="left" valign="top" charoff="50">Missing</td><td align="center" valign="top" char="(" charoff="50">187</td><td align="center" valign="top" char="(" charoff="50">164</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Alkaline phosphatase</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x0003c;300</td><td align="char" valign="top" char="(" charoff="50">715 (88.8)</td><td align="char" valign="top" char="(" charoff="50">620 (77.6)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02a7e;300</td><td align="char" valign="top" char="(" charoff="50">90 (11.2)</td><td align="char" valign="top" char="(" charoff="50">179 (22.4)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Mutations of KRAS, NRAF &#x00026; BRAF</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">All wild-type</td><td align="char" valign="top" char="(" charoff="50">299 (46.9)</td><td align="char" valign="top" char="(" charoff="50">293 (47.7)</td></tr><tr><td align="left" valign="top" charoff="50">At least one mutation</td><td align="char" valign="top" char="(" charoff="50">338 (53.1)</td><td align="char" valign="top" char="(" charoff="50">321 (52.3)</td></tr><tr><td align="left" valign="top" charoff="50">Missing</td><td align="center" valign="top" char="(" charoff="50">168</td><td align="center" valign="top" char="(" charoff="50">185</td></tr><tr><td align="left" valign="top" charoff="50">Included in per-protocol analysis</td><td align="char" valign="top" char="(" charoff="50">519 (64.5)</td><td align="char" valign="top" char="(" charoff="50">452 (56.6)</td></tr></tbody></table></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Hazard ratios and median survival times of ITT and per protocol populations by dNLR<sup>
<bold>a</bold>
</sup></title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="char" char="("/><col align="char" char=""/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Population</bold></th><th align="center" valign="top" charoff="50"><bold>Median survival time (Arm A</bold>
<italic><bold>vs</bold></italic>
<bold>Arm C)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>HR (80&#x00025; CI)</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value for interaction</bold></th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><bold>ITT</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">dNLR &#x0003c;2.2 (<italic>N</italic>=805)</td><td align="center" valign="top" charoff="50">19.2 <italic>vs</italic> 18.1</td><td align="char" valign="top" char="(" charoff="50">1.04 (0.936&#x02013;1.163)</td><td align="char" valign="top" char="." charoff="50">0.20</td></tr><tr><td align="left" valign="top" charoff="50">dNLR &#x02a7e;2.2 (<italic>N</italic>=799)</td><td align="center" valign="top" charoff="50">13.0 <italic>vs</italic> 11.9</td><td align="char" valign="top" char="(" charoff="50">1.21 (1.094&#x02013;1.335)</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><bold>Per protocol</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">dNLR &#x0003c;2.2 (<italic>N</italic>=519)</td><td align="center" valign="top" charoff="50">21.8 <italic>vs</italic> 21.5</td><td align="char" valign="top" char="(" charoff="50">1.06 (0.921&#x02013;1.224)</td><td align="char" valign="top" char="." charoff="50">0.26</td></tr><tr><td align="left" valign="top" charoff="50">dNLR &#x02a7e;2.2 (<italic>N</italic>=452)</td><td align="center" valign="top" charoff="50">16.6 <italic>vs</italic> 15.4</td><td align="char" valign="top" char="(" charoff="50">1.26 (1.099&#x02013;1.446)</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p><sup>a</sup>Adjusted for tumour status, number of metastases, alkaline phosphate and platelet count.</p></fn></table-wrap-foot></table-wrap></floats-group></article>